trial

Simvastatin Addition for Patients With Recent-onset Schizophrenia

NCTId NCT01999309
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 121 (actual)
Sponsored by Iris Sommer
Primary completion 2019-12-19
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
121 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2013-10
Primary completion
2019-12-19
Eligibility
ALL · 18 Years · 50 Years

Interventions & indications

Drugs
Simvastatin

Sponsors

Iris SommerLead Sponsor
Stanley Medical Research InstituteCollaborator

Investigators

1
Iris E.C. Sommer, Prof. Dr.Principal Investigator

Sites

2 total
Groningen, NetherlandsUtrecht, Netherlands

Linked catalysts

1
Simvastatin Addition for Patients With Recent-onset Schizophrenia — primary completion2019-12-19

Facts & assertions

4 sourced
Enrollment
121
Phase
PHASE3
Primary Completion Date
2019-12-19
Status
COMPLETED
relationships
The graph out of here
drug
Simvastatin
drug
lead_sponsor
Iris Sommer
company
collaborator
Stanley Medical Research Institute
company
indication
Schizophreniform Disorder
indication
Schizoaffective Disorder
indication
Psychotic Disorders
indication
investigator
Iris E.C. Sommer, Prof. Dr.
person